Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subj

Indication
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

Other upcoming events for AXSM

Phase 3 ReadoutPhase 3 Topline: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy and Safety of
Phase 3 ReadoutPhase 3 Topline: An Open-Label Study to Assess the Long-Term Safety and Efficacy of AXS-14 in the Management of Fibro
Patent ExpiryPatent/Exclusivity Expiry: SUNOSI

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subj — AXSM Phase 3 Readout | BioSniper